MADISON, Wis.--(BUSINESS WIRE)--Archeus Technologies, a clinical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address some of the most difficult-to-treat cancers, today announced the reconstitution of its Advisory Board, appointing five leaders with deep expertise across clinical development, drug discovery, and biopharmaceutical leadership. “The Advisory Board has been rebuilt to reflect where Archeus is today — a company with two